

# CITATION REPORT

List of articles citing

The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age

DOI: 10.1080/14767050802034545

Journal of Maternal-Fetal and Neonatal Medicine, 2008  
, 21, 279-87.

Source: <https://exaly.com/paper-pdf/44362066/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
251	Maternal serum placental growth factor (PLGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation. <b>2008</b> , 28, 1110-5		88
250	Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. <b>2008</b> , 32, 732-9		195
249	Soluble and membranous vascular endothelial growth factor receptor-1 in pregnancies complicated by pre-eclampsia. <b>2008</b> , 190, 477-89		37
248	Severe preeclampsia is characterized by increased placental expression of galectin-1. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2008</b> , 21, 429-42	2	54
247	Maternal serum adiponectin multimers in preeclampsia. <b>2009</b> , 37, 349-63		54
246	Maternal serum adiponectin multimers in patients with a small-for-gestational-age newborn. <b>2009</b> , 37, 623-35		23
245	First-trimester prediction of early preeclampsia: a possibility at last!. <b>2009</b> , 53, 747-8		28
244	Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation. <b>2009</b> , 124, e450-8		190
243	A role for menstruation in preconditioning the uterus for successful pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , <b>2009</b> , 200, 615.e1-6	6.4	104
242	Early onset preeclampsia and second trimester serum markers. <b>2009</b> , 29, 1109-17		14
241	Potential markers of preeclampsia--a review. <b>2009</b> , 7, 70		184
240	Tests to Predict Preeclampsia. <b>2009</b> , 189-211		2
239	A subset of patients destined to develop spontaneous preterm labor has an abnormal angiogenic/anti-angiogenic profile in maternal plasma: evidence in support of pathophysiologic heterogeneity of preterm labor derived from a longitudinal study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2009</b> , 22, 1100-08	2	59
238	A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2009</b> , 22, 1021-38	2	209
237	The perinatal implications of angiogenic factors. <b>2009</b> , 21, 111-6		34
236	Risk factors and prediction of preeclampsia. <b>2010</b> , 65, 1-12		13
235	Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia. <b>2010</b> , 35, 680-7		58

234	Angiogenic imbalances: the obstetric perspective. <i>American Journal of Obstetrics and Gynecology</i> , <b>2010</b> , 203, 17.e1-8	6.4	34
233	A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , <b>2010</b> , 202, 550.e1-10	6.4	24
232	Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. <i>American Journal of Obstetrics and Gynecology</i> , <b>2010</b> , 203, 383.e1-8	6.4	118
231	Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. <b>2010</b> , 30, 191-7		40
230	Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in the routine prenatal screening of Down syndrome. <b>2010</b> , 30, 471-7		44
229	First-trimester placental growth factor as a marker for hypertensive disorders and SGA. <b>2010</b> , 30, 565-70		24
228	First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia. <b>2010</b> , 117, 1384-9		76
227	Placental bed disorders in the genesis of the great obstetrical syndromes. 271-289		8
226	Periconceptual and early pregnancy approach. 243-255		1
225	Uterine artery Doppler in first-trimester pregnancy screening. <b>2010</b> , 53, 879-87		21
224	Microbial invasion of the amniotic cavity in pregnancies with small-for-gestational-age fetuses. <b>2010</b> , 38, 495-502		58
223	Microbial invasion of the amniotic cavity in preeclampsia as assessed by cultivation and sequence-based methods. <b>2010</b> , 38, 503-13		59
222	Characterization of the myometrial transcriptome and biological pathways of spontaneous human labor at term. <b>2010</b> , 38, 617-43		111
221	Increased risk of pre-eclampsia (PE) among women with the history of migraine. <b>2010</b> , 32, 159-65		19
220	Leukocytes of pregnant women with small-for-gestational age neonates have a different phenotypic and metabolic activity from those of women with preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 476-87	2	36
219	Angiogenic proteins as aid in the diagnosis and prediction of preeclampsia. <b>2010</b> , 242, 73-8		5
218	Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: the need for standardization in clinical practice. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 820-7	2	19
217	An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 1384-99		48

216	Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA?. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 857-68	2	29
215	Fetal death: a condition with a dissociation in the concentrations of soluble vascular endothelial growth factor receptor-2 between the maternal and fetal compartments. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 960-72	2	9
214	Unexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluid. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 794-805	2	17
213	Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2011</b> , 24, 1187-207	2	100
212	Decorin is a novel VEGFR-2-binding antagonist for the human extravillous trophoblast. <b>2011</b> , 25, 1431-43		96
211	Circulating predictive biomarkers in preeclampsia. <b>2011</b> , 1, 28-42		21
210	Relation between maternal angiogenic factors and utero-placental resistance in normal first- and second-trimester pregnancies. <b>2011</b> , 30, 401-7		6
209	Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks. <b>2011</b> , 29, 148-54		133
208	Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. <b>2011</b> , 66, 225-39		133
207	Is inflammation the cause of pre-eclampsia?. <b>2011</b> , 39, 1619-27		81
206	The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. <i>American Journal of Obstetrics and Gynecology</i> , <b>2011</b> , 204, 193-201	6.4	832
205	Circulating angiogenic and antiangiogenic factors in women with eclampsia. <i>American Journal of Obstetrics and Gynecology</i> , <b>2011</b> , 204, 152.e1-9	6.4	63
204	A molecular signature of an arrest of descent in human parturition. <i>American Journal of Obstetrics and Gynecology</i> , <b>2011</b> , 204, 177.e15-33	6.4	21
203	Midpregnancy levels of angiogenic markers in relation to maternal characteristics. <i>American Journal of Obstetrics and Gynecology</i> , <b>2011</b> , 204, 244.e1-12	6.4	31
202	Placental expression of angiogenic factors in Trisomy 13. <i>American Journal of Obstetrics and Gynecology</i> , <b>2011</b> , 204, 546.e1-4	6.4	14
201	Placental protein 13 (PP13/galectin-13) undergoes lipid raft-associated subcellular redistribution in the syncytiotrophoblast in preterm preeclampsia and HELLP syndrome. <i>American Journal of Obstetrics and Gynecology</i> , <b>2011</b> , 205, 156.e1-14	6.4	42
200	Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , <b>2011</b> , 205, 366.e1-5	6.4	52
199	Pre-eclampsia: a maternal manifestation of a fetal adaptive response?. <b>2011</b> , 38, 367-70		10

198	Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review. <b>2011</b> , 9, 77		25
197	First trimester screening for intra-uterine growth restriction and early-onset pre-eclampsia. <b>2011</b> , 31, 955-61		25
196	Stability of first trimester placental growth factor in serum and whole blood. <b>2011</b> , 31, 1193-7		16
195	Antecedents of chronic lung disease following three patterns of early respiratory disease in preterm infants. <b>2011</b> , 96, F114-20		29
194	Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction. <b>2011</b> , 173, 630-9		60
193	Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. <b>2011</b> , 39, 641-52		172
192	Identification of high-risk patients for adverse pregnancy outcome based on multivariate logistic regression analysis at 20-23 gestational weeks. <b>2011</b> , 39, 667-72		3
191	Biomarkers in Preeclampsia. <b>2011</b> , 385-426		2
190	Polymorphisms in maternal and fetal genes encoding for proteins involved in extracellular matrix metabolism alter the risk for small-for-gestational-age. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2011</b> , 24, 362-80	2	15
189	Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. <b>2012</b> , 122, 43-52		109
188	Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2012</b> , 25, 1135-41	2	14
187	The vascular endothelial growth factor family in adverse pregnancy outcomes. <b>2012</b> , 18, 436-57		139
186	First trimester serum angiogenic/anti-angiogenic status in twin pregnancies: relationship with assisted reproduction technology. <b>2012</b> , 27, 358-65		16
185	Mechanisms in decorin regulation of vascular endothelial growth factor-induced human trophoblast migration and acquisition of endothelial phenotype. <b>2012</b> , 87, 59		55
184	Glycogen phosphorylase isoenzyme BB plasma concentration is elevated in pregnancy and preterm preeclampsia. <b>2012</b> , 59, 274-82		10
183	Comparative Study of Endothelial Function and Uterine Artery Doppler Velocimetry between Pregnant Women with or without Preeclampsia Development. <b>2012</b> , 2012, 909315		5
182	Marqueurs biologiques de la prééclampsie. <b>2012</b> , 7, 1-7		
181	Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies. <b>2012</b> , 23, 779-84		16

180	Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2012</b> , 25, 498-507	2	104
179	Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2012</b> , 25, 2651-7	2	53
178	ABO and RhD blood groups and gestational hypertensive disorders: a population-based cohort study. <b>2012</b> , 119, 1232-7		21
177	Proangiogenic immature myeloid cells populate the human placenta and their presence correlates with placental and birthweight. <i>American Journal of Obstetrics and Gynecology</i> , <b>2012</b> , 207, 141.e1-5	6.4	9
176	Combination of uterine artery Doppler velocimetry and maternal serum placental growth factor estimation in predicting occurrence of pre-eclampsia in early second trimester pregnancy: a prospective cohort study. <b>2012</b> , 161, 144-51		17
175	Early pregnancy screening for hypertensive disorders in women without a-priori high risk. <b>2012</b> , 40, 398-405		15
174	Recent biomarkers for the identification of patients at risk for preeclampsia: the role of uteroplacental ischemia. <b>2012</b> , 6, 121-30		13
173	Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction. <b>2012</b> , 91, 1388-94		27
172	Endoglin in pregnancy complicated by fetal intrauterine growth restriction in normotensive and preeclamptic pregnant women: a comparison between preeclamptic patients with appropriate-for-gestational-age weight infants and healthy pregnant women. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2012</b> , 25, 806-11	2	6
171	Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , <b>2012</b> , 207, 407.e1-7	6.4	104
170	Distal-less 3 haploinsufficiency results in elevated placental oxidative stress and altered fetal growth kinetics in the mouse. <b>2012</b> , 33, 830-8		10
169	Early-Onset Preeclampsia and HELLP Syndrome: An Overview. <b>2012</b> , 1867-1891		8
168	A cohort evaluation on arterial stiffness and hypertensive disorders in pregnancy. <i>BMC Pregnancy and Childbirth</i> , <b>2012</b> , 12, 160	3.2	14
167	Predictive Value of Maternal Serum Markers for Preeclampsia. <b>2012</b> , 27, 91		
166	Relationships among maternal nutrient intake and placental biomarkers during the 1st trimester in low-income women. <b>2012</b> , 285, 891-9		8
165	Review: Biochemical markers to predict preeclampsia. <b>2012</b> , 33 Suppl, S42-7		135
164	Is serum placental growth factor more effective as a biomarker in predicting early onset preeclampsia in early second trimester than in first trimester of pregnancy?. <b>2013</b> , 287, 865-73		18
163	Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome. <b>2013</b> , 463, 445-58		34

162	The role of B cells in pregnancy: the good and the bad. <i>American Journal of Reproductive Immunology</i> , <b>2013</b> , 69, 408-12	3.8	47
161	Growth factors in preeclampsia: a vascular disease model. A failed vasodilation and angiogenic challenge from pregnancy onwards?. <b>2013</b> , 24, 411-25		35
160	Can maternal serum placental growth factor estimation in early second trimester predict the occurrence of early onset preeclampsia and/or early onset intrauterine growth restriction? A prospective cohort study. <b>2013</b> , 39, 881-90		20
159	Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , <b>2013</b> , 208, 287.e1-287.e15	6.4	103
158	miR-210 inhibits trophoblast invasion and is a serum biomarker for preeclampsia. <b>2013</b> , 183, 1437-1445		104
157	Prediction of early and late pre-eclampsia from maternal characteristics, uterine artery Doppler and markers of vasculogenesis during first trimester of pregnancy. <b>2013</b> , 41, 538-44		83
156	Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia. <b>2013</b> , 33, 149-55		12
155	Circulating levels of neutrophil gelatinase-associated lipocalin (NGAL) correlate with the presence and severity of preeclampsia. <b>2013</b> , 20, 1083-9		18
154	First-trimester serum soluble fms-like tyrosine kinase-1, free vascular endothelial growth factor, placental growth factor and uterine artery Doppler in preeclampsia. <b>2013</b> , 33, 670-4		28
153	Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2013</b> , 26, 1359-70	2	30
152	Perfusion with magnesium sulfate increases sFlt-1 secretion only in the fetal side of placenta of women with preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2013</b> , 26, 116-22	2	4
151	Placental trophoblast cell differentiation: physiological regulation and pathological relevance to preeclampsia. <b>2013</b> , 34, 981-1023		223
150	Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death. <i>American Journal of Obstetrics and Gynecology</i> , <b>2013</b> , 208, 310.e1-310.e11	6.4	48
149	Maternal serum placental growth factor, pregnancy-associated plasma protein-a and free human chorionic gonadotrophin at 30-33 weeks in the prediction of pre-eclampsia. <b>2013</b> , 33, 164-72		24
148	Novel biomarkers for predicting intrauterine growth restriction: a systematic review and meta-analysis. <b>2013</b> , 120, 681-94		108
147	Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?. <b>2013</b> , 120, 1183-91		67
146	Maternal plasma soluble TRAIL is decreased in preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2014</b> , 27, 217-27	2	13
145	Early prediction of preeclampsia. <b>2014</b> , 2014, 297397		135



144	The anti-aging factor Eklotho during human pregnancy and its expression in pregnancies complicated by small-for-gestational-age neonates and/or preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2014</b> , 27, 449-57	2	13
143	Angiogenic factors vs Doppler surveillance in the prediction of adverse outcome among late-pregnancy small-for-gestational-age fetuses. <b>2014</b> , 43, 533-40		46
142	Evolutionary origins of the placental expression of chromosome 19 cluster galectins and their complex dysregulation in preeclampsia. <b>2014</b> , 35, 855-65		63
141	Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2014</b> , 27, 132-44	2	55
140	A longitudinal study of circulating angiogenic and antiangiogenic factors and AT1-AA levels in preeclampsia. <b>2014</b> , 37, 753-8		47
139	Histologic differences in placentas of preeclamptic/eclamptic gestations by birthweight, placental weight, and time of onset. <b>2014</b> , 17, 181-9		22
138	Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2014</b> , 27, 1038-48	2	33
137	Added value of angiogenic factors for the prediction of early and late preeclampsia in the first trimester of pregnancy. <b>2014</b> , 35, 258-66		29
136	ANGIOGENIC IMBALANCES IN THE PATHOGENESIS OF PREGNANCY COMPLICATIONS. <b>2014</b> , 25, 42-58		
135	The effect of prenatal pravastatin treatment on altered fetal programming of postnatal growth and metabolic function in a preeclampsia-like murine model. <i>American Journal of Obstetrics and Gynecology</i> , <b>2014</b> , 210, 542.e1-7	6.4	26
134	Angiogenic factors in diagnosis, management, and research in preeclampsia. <b>2014</b> , 63, 198-202		89
133	Longitudinal changes in maternal soluble endoglin and angiopoietin-2 in women at risk for pre-eclampsia. <b>2014</b> , 44, 402-10		11
132	Use of first or second trimester serum markers, or both, to predict preeclampsia. <b>2014</b> , 4, 271-8		11
131	Concentrations of endothelial nitric oxide synthase, angiotensin-converting enzyme, vascular endothelial growth factor and placental growth factor in maternal blood and maternal metabolic status in pregnancy complicated by hypertensive disorders. <b>2014</b> , 28, 670-6		15
130	First-trimester maternal factors and biomarker screening for preeclampsia. <b>2014</b> , 34, 618-27		87
129	Placental development during early pregnancy in sheep: effects of embryo origin on vascularization. <b>2014</b> , 147, 639-48		30
128	Second- and third-trimester biochemical and ultrasound markers predictive of ischemic placental disease. <b>2014</b> , 38, 167-76		12
127	Difference of endothelial function during pregnancies as a method to predict preeclampsia. <b>2014</b> , 290, 471-7		22



126	Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice. <i>PLoS ONE</i> , <b>2015</b> , 10, e0119547	3.7	28
125	Midtrimester maternal plasma concentrations of angiopoietin 1, angiopoietin 2, and placental growth factor in pregnant women who subsequently develop preeclampsia. <b>2015</b> , 58, 10-6		8
124	Prediction of Fetal Growth Restriction by Analyzing the Messenger RNAs of Angiogenic Factor in the Plasma of Pregnant Women. <b>2015</b> , 22, 743-9		7
123	A prior placenta accreta is an independent risk factor for post-partum hemorrhage in subsequent gestations. <b>2015</b> , 187, 20-4		10
122	Forms of Circulating Luteinizing Hormone Human Chorionic Gonadotropin Receptor for the Prediction of Early and Late Preeclampsia in the First Trimester of Pregnancy. <b>2015</b> , 38, 94-102		4
121	Update on the pathophysiological implications and clinical role of angiogenic factors in pregnancy. <b>2015</b> , 37, 81-92		47
120	Angiogenic biomarkers in pregnancy: defining maternal and fetal health. <b>2015</b> , 94, 820-32		19
119	Early pregnancy maternal and fetal angiogenic factors and fetal and childhood growth: the Generation R Study. <b>2015</b> , 30, 1302-13		17
118	Concentrations of eNOS, VEGF, ACE and PlGF in maternal blood as predictors of impaired fetal growth in pregnancy complicated by gestational hypertension/preeclampsia. <b>2015</b> , 34, 17-23		7
117	Whole mount immunofluorescence analysis of placentas from normotensive versus preeclamptic pregnancies. <b>2015</b> , 36, 1310-7		5
116	Maternal plasma fetuin-A concentration is lower in patients who subsequently developed preterm preeclampsia than in uncomplicated pregnancy: a longitudinal study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2015</b> , 28, 1260-1269	2	3
115	First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors. <b>2015</b> , 35, 183-91		80
114	Pre-eclampsia: its pathogenesis and pathophysiology. <b>2016</b> , 27, 71-8		170
113	Hypertensive pathologies and egg donation pregnancies: Results of a large comparative cohort study. <b>2016</b> , 106, 284-90		25
112	Nested case-control study reveals increased levels of urinary proteins from human kidney toxicity panels in women predicted to develop preeclampsia. <b>2016</b> , 48, 2051-2059		5
111	Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study. <i>American Journal of Obstetrics and Gynecology</i> , <b>2016</b> , 214, e1-e17	6.4	65
110	Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia. <b>2016</b> , 47, 324-31		30
109	Circulating Maternal Total Cell-Free DNA, Cell-Free Fetal DNA and Soluble Endoglin Levels in Preeclampsia: Predictors of Adverse Fetal Outcome? A Cohort Study. <b>2016</b> , 20, 135-49		13

108	Down-regulation of placental neuropilin-1 in fetal growth restriction. <i>American Journal of Obstetrics and Gynecology</i> , <b>2016</b> , 214, 279.e1-279.e9	6.4	13
107	The use of ultrasound and other markers for early detection of preeclampsia. <b>2016</b> , 12, 199-207		17
106	Diagnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease. <b>2016</b> , 89, 874-85		91
105	Analysis of changes in maternal circulating angiogenic factors throughout pregnancy for the prediction of preeclampsia. <b>2016</b> , 36, 172-7		17
104	The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2016</b> , 29, 1214-28	2	42
103	Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD). <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2016</b> , 29, 855-62	2	36
102	Dose-response association between maternal body mass index and small for gestational age: a meta-analysis. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2017</b> , 30, 213-218	2	7
101	Changes in uterine artery Doppler velocimetry and circulating angiogenic factors in the first half of pregnancies delivering a small-for-gestational-age neonate. <b>2017</b> , 49, 357-363		16
100	Is an episode of suspected preterm labor that subsequently leads to a term delivery benign?. <i>American Journal of Obstetrics and Gynecology</i> , <b>2017</b> , 216, 89-94	6.4	15
99	The maternal plasma proteome changes as a function of gestational age in normal pregnancy: a longitudinal study. <i>American Journal of Obstetrics and Gynecology</i> , <b>2017</b> , 217, 67.e1-67.e21	6.4	49
98	Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. <i>American Journal of Obstetrics and Gynecology</i> , <b>2017</b> , 217, 282-302	6.4	139
97	Independent risk factors for a small placenta and a small-for-gestational-age infant at 35-41 weeks of gestation: An association with circulating angiogenesis-related factor levels at 19-31 weeks of gestation. <b>2017</b> , 43, 1285-1292		2
96	Failure of physiologic transformation of spiral arteries, endothelial and trophoblast cell activation, and acute atherosclerosis in the basal plate of the placenta. <i>American Journal of Obstetrics and Gynecology</i> , <b>2017</b> , 216, 287.e1-287.e16	6.4	81
95	Biomarkers in Preeclampsia. <b>2017</b> , 555-594		2
94	The prediction of fetal death with a simple maternal blood test at 20-24 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio). <i>American Journal of Obstetrics and Gynecology</i> , <b>2017</b> , 217, 682.e1-682.e13	6.4	19
93	The pregnancy outcome prediction (POP) study: Investigating the relationship between serial prenatal ultrasonography, biomarkers, placental phenotype and adverse pregnancy outcomes. <b>2017</b> , 59, S17-S25		35
92	Maternal serum placental growth factor and pregnancy-associated plasma protein A measured in the first trimester as parameters of subsequent pre-eclampsia and small-for-gestational-age infants: A prospective observational study. <b>2017</b> , 60, 154-162		17
91	Screening for Preeclampsia. <b>2018</b> , 5, 31-36		

90	Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers. <i>American Journal of Obstetrics and Gynecology</i> , <b>2018</b> , 218, S725-S737	6.4	64
89	Placental oxidative stress and maternal endothelial function in pregnant women with normotensive fetal growth restriction. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2018</b> , 31, 1051-1057		8
88	Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia - a longitudinal study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2018</b> , 31, 418-432	2	17
87	Angiogenic and antiangiogenic factors in preeclampsia. <b>2018</b> , 214, 7-14		34
86	Screening and prevention of pre-term pre-eclampsia - A prime time to act. <b>2018</b> , 21, 187-190		1
85	Maternal total cell-free DNA in preeclampsia and fetal growth restriction: Evidence of differences in maternal response to abnormal implantation. <i>PLoS ONE</i> , <b>2018</b> , 13, e0200360	3.7	20
84	Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1661	8.4	79
83	Angiogenic capacity in pre-eclampsia and uncomplicated pregnancy estimated by assay of angiogenic proteins and an in vitro vasculogenesis/angiogenesis test. <b>2019</b> , 22, 67-74		4
82	The two-stage placental model of preeclampsia: An update. <b>2019</b> , 134-135, 1-10		126
81	Placental Galectins Are Key Players in Regulating the Maternal Adaptive Immune Response. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1240	8.4	25
80	Maternal vascular malformation in the placenta is an indicator for fetal growth restriction irrespective of neonatal birthweight. <b>2019</b> , 87, 8-15		7
79	Longitudinal changes in placental biomarkers in women with early versus late placental dysfunction. <b>2019</b> , 38, 268-277		1
78	The prediction of early preeclampsia: Results from a longitudinal proteomics study. <i>PLoS ONE</i> , <b>2019</b> , 14, e0217273	3.7	41
77	Can Fetal Growth Velocity and First Trimester Maternal Biomarkers Improve the Prediction of Small-for-Gestational Age and Adverse Neonatal Outcome?. <b>2019</b> , 46, 274-284		5
76	Screening for preeclampsia in the first trimester of pregnancy in routine clinical practice in Hungary. <b>2019</b> , 300, 11-19		1
75	[Potential value of placental angiogenic factors as biomarkers in preeclampsia for clinical physicians]. <b>2019</b> , 15, 413-429		3
74	Placental Growth Factor as an Indicator of Maternal Cardiovascular Risk After Pregnancy. <b>2019</b> , 139, 1698-1709		21
73	Pre-eclampsia: pathogenesis, novel diagnostics and therapies. <b>2019</b> , 15, 275-289		259

72	The ability of thromboelastography parameters to predict severe pre-eclampsia when measured during early pregnancy. <b>2019</b> , 145, 170-175		6
71	The profiles of soluble adhesion molecules in the "great obstetrical syndromes". <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2019</b> , 32, 2113-2136	2	14
70	ELABELA plasma concentrations are increased in women with late-onset preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2020</b> , 33, 5-15	2	26
69	Prediction of Preeclampsia in Nulliparous Women according to First Trimester Maternal Factors and Serum Markers. <b>2020</b> , 47, 277-283		6
68	Reproductive immunomodulatory functions of B cells in pregnancy. <b>2020</b> , 39, 53-66		15
67	Reconciling the distinct roles of angiogenic/anti-angiogenic factors in the placenta and maternal circulation of normal and pathological pregnancies. <b>2020</b> , 23, 105-117		39
66	A more accurate prediction to rule in and rule out pre-eclampsia using the sFlt-1/PlGF ratio and NT-proBNP as biomarkers. <b>2020</b> , 58, 399-407		4
65	First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , <b>2020</b> , 222, 374.e1-374.e9	6.4	8
64	Association between the fetal cerebroplacental ratio and biomarkers of hypoxia and angiogenesis in the maternal circulation at term. <b>2020</b> , 245, 198-204		2
63	Maternal whole blood mRNA signatures identify women at risk of early preeclampsia: a longitudinal study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2021</b> , 34, 3463-3474	2	16
62	Role of sFlt-1 and PlGF in the screening of small-for-gestational age neonates during pregnancy: A systematic review. <b>2020</b> , 57, 44-58		4
61	Evaluation of Angiogenic Factors (PlGF and sFlt-1) in Pre-eclampsia Diagnosis. <b>2020</b> , 42, 697-704		1
60	Mechanisms of Key Innate Immune Cells in Early- and Late-Onset Preeclampsia. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1864	8.4	34
59	An assessment of serum-dependent impacts on intracellular accumulation and genomic response of per- and polyfluoroalkyl substances in a placental trophoblast model. <b>2020</b> , 35, 1395-1405		9
58	Temperature and preeclampsia: Epidemiological evidence that perturbation in maternal heat homeostasis affects pregnancy outcome. <i>PLoS ONE</i> , <b>2020</b> , 15, e0232877	3.7	12
57	Current update of first trimester preeclampsia screening in Asia. <b>2021</b> , 47, 26-33		
56	Maternal plasma soluble neuropilin-1 is downregulated in fetal growth restriction complicated by abnormal umbilical artery Doppler: a pilot study. <b>2021</b> , 58, 716-721		
55	FIGO (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction. <b>2021</b> , 152 Suppl 1, 3-57		28

54	Prediction of preeclampsia throughout gestation with maternal characteristics and biophysical and biochemical markers: a longitudinal study.. <i>American Journal of Obstetrics and Gynecology</i> , <b>2022</b> , 226, 126.e1-126.e22	6.4	2
53	Unravelling the potential of angiogenic factors for the early prediction of preeclampsia. <b>2021</b> , 44, 756-769		1
52	Use of FMF algorithm for prediction of preeclampsia in high risk pregnancies: a single center longitudinal study. <b>2021</b> , 40, 171-179		0
51	Chronic hypertension and superimposed preeclampsia: screening and diagnosis.. <i>American Journal of Obstetrics and Gynecology</i> , <b>2022</b> , 226, S1182-S1195	6.4	1
50	Serial measurement of soluble endoglin for risk assessment at the diagnosis of fetal growth restriction. <i>International Journal of Clinical Practice</i> , <b>2021</b> , e14840	2.9	0
49	Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. <i>PLoS ONE</i> , <b>2012</b> , 7, e48259	3.7	41
48	Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. <i>PLoS ONE</i> , <b>2012</b> , 7, e50208	3.7	57
47	In vivo experiments reveal the good, the bad and the ugly faces of sFlt-1 in pregnancy. <i>PLoS ONE</i> , <b>2014</b> , 9, e110867	3.7	21
46	The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0181468	3.7	52
45	Angiogenic factors and the risk of preeclampsia: A systematic review and meta-analysis. <i>International Journal of Reproductive BioMedicine</i> , <b>2019</b> , 17,	1.3	6
44	Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis. <i>Health Technology Assessment</i> , <b>2016</b> , 20, 1-160	4.4	22
43	Differential Secretion of Angiopoietic Factors and Expression of MicroRNA in Umbilical Cord Blood from Healthy Appropriate-For-Gestational-Age Preterm and Term Newborns-. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	6
42	IMMUNOLOGICAL AND PATHOMORPHOLOGICAL ASPECTS OF EARLY AND LATE PREECLAMPSIA. <i>Medical Immunology (Russia)</i> , <b>2021</b> , 23, 845-852	0.5	0
41	Disseminated intravascular coagulation in pregnancy: New insights. <i>Thrombosis Update</i> , <b>2021</b> , 100083	0.9	0
40	Adipsin of the Alternative Complement Pathway Is a Potential Predictor for Preeclampsia in Early Pregnancy. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 702385	8.4	0
39	[Can pre-eclampsia be predicted?]. <i>Tidsskrift for Den Norske Laegeforening</i> , <b>2011</b> , 131, 806-7	3.5	
38	THE ROLE OF BIOCHEMICAL MARKERS IN THE RISK STRATIFICATION FOR DEVELOPMENT OF PREECLAMPSIA: THE CLINICIAN'S VIEW. <i>V F Snegirev Archives of Obstetrics and Gynecology</i> , <b>2017</b> , 4, 181-186	0.1	0.1
37	The Effect of Garlic Capsule on the Prevention of Preeclampsia in High-risk Turkmen Pregnant Women. <i>Jundishapur Journal of Natural Pharmaceutical Products</i> , <b>2019</b> , 15,	1.1	

36	Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an american ophthalmological society thesis). <i>Transactions of the American Ophthalmological Society</i> , <b>2010</b> , 108, 96-119		33
35	Biochemical markers for prediction of preeclampsia: review of the literature. <i>Journal of Prenatal Medicine</i> , <b>2011</b> , 5, 69-77		14
34	The imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsia. <i>Iranian Journal of Reproductive Medicine</i> , <b>2015</b> , 13, 251-62		15
33	Evaluation of Serum Biomarkers and Other Diagnostic Modalities for Early Diagnosis of Preeclampsia. <i>Journal of Family &amp; Reproductive Health</i> , <b>2019</b> , 13, 56-69	0.6	6
32	Circulating s-Endoglin concentrations in non-obese patients with gestational diabetes mellitus.. <i>Journal of Obstetrics and Gynaecology</i> , <b>2022</b> , 1-6	1.3	0
31	The etiology of preeclampsia.. <i>American Journal of Obstetrics and Gynecology</i> , <b>2022</b> , 226, S844-S866	6.4	9
30	Preeclampsia and eclampsia: the conceptual evolution of a syndrome.. <i>American Journal of Obstetrics and Gynecology</i> , <b>2022</b> , 226, S786-S803	6.4	7
29	Longitudinal changes in serum immune markers during normal pregnancy in a North-Indian population.. <i>American Journal of Reproductive Immunology</i> , <b>2022</b> , e13531	3.8	0
28	Maternal blood angiogenic factors and the prediction of critical adverse perinatal outcome among SGA pregnancies.. <i>American Journal of Perinatology</i> , <b>2022</b> ,	3.3	
27	Modified multiple marker aneuploidy screening as a primary screening test for preeclampsia.. <i>BMC Pregnancy and Childbirth</i> , <b>2022</b> , 22, 190	3.2	1
26	Biochemical markers in the pathogenesis of preeclampsia: novel link between placental growth factor and interleukin-6.. <i>Molecular and Cellular Biochemistry</i> , <b>2022</b> , 1	4.2	0
25	Maternal preconception and pregnancy tobacco and cannabis use in relation to placental developmental markers: a population-based study.. <i>Reproductive Toxicology</i> , <b>2022</b> ,	3.4	0
24	Data_Sheet_1.zip. <b>2018</b> ,		
23	Image_1.pdf. <b>2018</b> ,		
22	Image_10.pdf. <b>2018</b> ,		
21	Image_11.pdf. <b>2018</b> ,		
20	Image_12.pdf. <b>2018</b> ,		
19	Image_13.pdf. <b>2018</b> ,		

18 Image\_2.pdf. **2018**,

17 Image\_3.pdf. **2018**,

16 Image\_4.pdf. **2018**,

15 Image\_5.pdf. **2018**,

14 Image\_6.pdf. **2018**,

13 Image\_7.pdf. **2018**,

12 Image\_8.pdf. **2018**,

11 Image\_9.pdf. **2018**,

10 Presentation\_1.pdf. **2019**,

9 Pregnancy Imparts Distinct Systemic Adaptive Immune Function. 0

8 Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology. **2022**, 227, 615.e1-615.e25 3

7 Human Plasma Proteome During Normal Pregnancy. 0

6 Angiogenic factors assessment in pre-eclampsia high risk population for the prediction of small-for-gestational age neonates: A prospective longitudinal study. 0

5 Preeclampsia at term can be classified into two clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood. **2022**, 1

4 Soluble suppression of tumorigenicity-2 in pregnancy with a small-for-gestational-age fetus and with preeclampsia. 1-11 0

3 Similar Pro- and Antiangiogenic Profiles Close to Delivery in Different Clinical Presentations of Two Pregnancy Syndromes: Preeclampsia and Fetal Growth Restriction. **2023**, 24, 972 2

2 Proteomic profile of extracellular vesicles in maternal plasma of women with fetal death. **2023**, 36, 0

1 Perspectives on the Use of Placental Growth Factor (PLGF) in the Prediction and Diagnosis of Pre-Eclampsia: Recent Insights and Future Steps. Volume 15, 255-271 1



